Clinical trials: Ovarian Epithelial Cancer Recurrent
Ovarian Cancer
A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
This is an open-label, single-arm, two-stage, multicenter Phase II study evaluating the efficacy and safety of bevacizumab in women with platinum resistant, advanced (Stage III or IV) EOC (epithelial ovarian cancer) or PPC…
- Trial name
- NCT00097019
- Testing
- bevacizumab
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.
- Trial name
- NCT02004093
- Testing
- pertuzumab, paclitaxel, gemcitabine
- Where
- 34 sites in Belgium, Canada and 7 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
- Conditions
- Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer, Relapsed Fallopian Tube Cancer
- Trial name
- NCT01940172
- Testing
- Birinapant, Conatumumab
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- TetraLogic Pharmaceuticals
Ovarian Cancer
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
[Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in actual clinical use. 1. ADR development in actual clinical use 2. Factors which may affect safety and efficacy 3.
- Trial name
- NCT03505307
- Volunteers
- 846 people
- Sponsor
- AstraZeneca
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Ovarian Cancer, Fallopian Tube Cancer
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- VITALIA (NCT03905902)
- Testing
- DCVAC/OvCa
- Sponsor
- SOTIO a.s.
Ovarian Cancer, Merkel Cell Carcinoma
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Ovarian Cancer, Merkel Cell Carcinoma, SCLC
- Trial name
- NCT00346385
- Testing
- BB-10901
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 97 people
- Sponsor
- ImmunoGen, Inc.
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Ovarian Cancer
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or…
- Trial name
- ZACFAST (NCT00862836)
- Testing
- Vandetanib
- Where
- 5 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Neoplasms
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic…
- Trial name
- NCT00396591
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The study is a multicenter, Phase Ib/IIa, open-label, dose-escalation study to evaluate the safety and tolerability of orally administered KAND567 in combination with carboplatin therapy, and to determine the Recommended Phase II…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- KANDOVA (NCT06087289)
- Testing
- KAND567, Carboplatin
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 18 people
- Sponsor
- Novakand Pharma AB
Ovarian Neoplasms
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.
- Trial name
- NCT00710762
- Testing
- BIBF1120
- Where
- 11 sites in United Kingdom
- Volunteers
- 89 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR.
- Trial name
- NCT00073541
- Testing
- EMD 72000
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- EMD Serono
Solid Tumor, Adult, Solid Tumor Cancer
Study of DF6215 in Patients With Advanced Solid Tumors
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced…
- Trial name
- NCT06108479
- Testing
- DF6215, pembrolizumab, KEYTRUDA®
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Dragonfly Therapeutics
Breast Cancer, Ovarian Epithelial Cancer Recurrent
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the…
- Conditions
- Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02014337
- Testing
- Mifepristone and Eribulin in combination
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Corcept Therapeutics
Ovarian Cancer
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and…
- Trial name
- NCT01133756
- Testing
- Lenvatinib, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eisai Inc.